{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,29]],"date-time":"2026-03-29T17:47:34Z","timestamp":1774806454533,"version":"3.50.1"},"reference-count":16,"publisher":"The Journal of Rheumatology","issue":"3","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["J Rheumatol"],"accepted":{"date-parts":[[2025,11,4]]},"published-print":{"date-parts":[[2026,3]]},"abstract":"<jats:sec>\n                    <jats:title>Objective<\/jats:title>\n                    <jats:p>Experiences with the antimalarial quinacrine for systemic lupus erythematosus (SLE) and cutaneous lupus erythematosus (CLE) remain underexplored. We evaluated and compared dermatologists\u2019 and rheumatologists\u2019 experiences with quinacrine in managing SLE and\/or CLE.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>We sent a structured survey to 102 SLE specialists within the Systemic Lupus International Collaborating Clinics (SLICC) and the Canadian Network for Improved Outcomes in Systemic Lupus Erythematosus (CaNIOS), and 200 members of the Rheumatologic Dermatology Society (RDS). Participants responded to questions on self-reported quinacrine prescription history, perceived clinical benefit, reasons for drug discontinuation, and barriers to prescribing.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>A total of 20 dermatologists from RDS and 40 SLICC and CaNIOS members responded to the survey. All RDS participants (100%) had previously prescribed quinacrine, compared to 17\/40 (43%) of SLICC\/CaNIOS participants. The majority of quinacrine prescribers (100% RDS, 12\/17 [71%] SLICC\/CaNIOS) had prescribed quinacrine in combination with another antimalarial. Hydroxychloroquine (HCQ) or chloroquine (CQ) intolerance (65% RDS, 47% SLICC\/CaNIOS) and HCQ\/CQ-related retinal toxicity (50% RDS, 24% SLICC\/CaNIOS) were other reasons for prescribing quinacrine. Clinical benefit was reported by 19\/20 (95%) of RDS and 12\/17 (71%) of SLICC\/CaNIOS clinicians, and discontinuations were less frequent among RDS (5\/20 [25%] reported none) compared to SLICC\/CaNIOS (all 17 reported \u2265 1). Availability and cost of quinacrine were primary prescribing barriers.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>Surveyed dermatologists and rheumatologists differed in their experience with quinacrine for CLE and SLE, respectively. Availability remains a key barrier to prescribing, underscoring the need to address supply issues and conduct further research to optimize quinacrine use in SLE and CLE.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.3899\/jrheum.2025-0757","type":"journal-article","created":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T14:05:18Z","timestamp":1764597918000},"page":"292-296","source":"Crossref","is-referenced-by-count":0,"title":["A Global Survey of Quinacrine Use in Systemic and Cutaneous Lupus Erythematosus"],"prefix":"10.3899","volume":"53","author":[{"ORCID":"https:\/\/orcid.org\/0009-0006-4470-5362","authenticated-orcid":false,"given":"Sarah","family":"Aly","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gilda","family":"Parastandehchehr","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9515-2802","authenticated-orcid":false,"given":"Sasha","family":"Bernatsky","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7727-5879","authenticated-orcid":false,"given":"\u00c9velyne","family":"Vinet","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8077-8394","authenticated-orcid":false,"given":"Laurent","family":"Arnaud","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1555-9021","authenticated-orcid":false,"given":"Nathalie","family":"Costedoat-Chalumeau","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7278-2596","authenticated-orcid":false,"given":"Paul R.","family":"Fortin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8962-4404","authenticated-orcid":false,"given":"John A.","family":"Reynolds","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1721-190X","authenticated-orcid":false,"given":"J. Carter","family":"Thorne","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5177-2076","authenticated-orcid":false,"given":"Zahi","family":"Touma","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2502-1372","authenticated-orcid":false,"given":"Daniel","family":"Wallace","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3030-5369","authenticated-orcid":false,"given":"Victoria P.","family":"Werth","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wendy","family":"Singer","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9732-616X","authenticated-orcid":false,"given":"Arielle","family":"Mendel","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"2262","published-online":{"date-parts":[[2025,12,1]]},"reference":[{"key":"2026032910412619000_53.3.292.1","first-page":"e30330","article-title":"An overview of systemic lupus erythematosus (SLE) pathogenesis, classification, and management","volume":"14","author":"Ameer","year":"2022","journal-title":"Cureus"},{"key":"2026032910412619000_53.3.292.2","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2012-202322"},{"key":"2026032910412619000_53.3.292.3","doi-asserted-by":"publisher","DOI":"10.1136\/ard.2008.101766"},{"key":"2026032910412619000_53.3.292.4","doi-asserted-by":"publisher","DOI":"10.1191\/096120300678828163"},{"key":"2026032910412619000_53.3.292.5","doi-asserted-by":"publisher","DOI":"10.1038\/nrrheum.2012.106"},{"key":"2026032910412619000_53.3.292.6","doi-asserted-by":"crossref","first-page":"1453","DOI":"10.1001\/jamaophthalmol.2014.3459","article-title":"The risk of toxic retinopathy in patients on long-term hydroxychloroquine therapy","volume":"132","author":"Melles","year":"2014","journal-title":"JAMA Ophthalmol"},{"key":"2026032910412619000_53.3.292.7","doi-asserted-by":"publisher","DOI":"10.1111\/bjd.15312"},{"key":"2026032910412619000_53.3.292.8","unstructured":"US Food and Drug Administration . Compounding safety information: quinacrine hydrochloride; 2023. [Internet. Accessed November 21, 2025.] Available from: https:\/\/www.fda.gov\/drugs\/human-drug-compounding\/compounding-safety-information-quinacrine-hydrochloride"},{"key":"2026032910412619000_53.3.292.9","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1016\/j.jaad.2017.09.061","article-title":"Antimalarial drug toxicities in patients with cutaneous lupus and dermatomyositis: a retrospective cohort study","volume":"78","author":"Mittal","year":"2018","journal-title":"J Am Acad Dermatol"},{"key":"2026032910412619000_53.3.292.10","doi-asserted-by":"publisher","DOI":"10.1136\/lupus-2020-000430"},{"key":"2026032910412619000_53.3.292.11","doi-asserted-by":"crossref","first-page":"374","DOI":"10.1016\/j.jaad.2017.03.027","article-title":"The quinacrine experience in a population of patients with cutaneous lupus erythematosus and dermatomyositis","volume":"77","author":"Mittal","year":"2017","journal-title":"J Am Acad Dermatol"},{"key":"2026032910412619000_53.3.292.12","doi-asserted-by":"publisher","DOI":"10.1191\/096120398678919778"},{"key":"2026032910412619000_53.3.292.13","doi-asserted-by":"publisher","DOI":"10.3899\/jrheum.120572"},{"key":"2026032910412619000_53.3.292.14","doi-asserted-by":"crossref","first-page":"461","DOI":"10.1002\/acr.24130","article-title":"2020 American College of Rheumatology guideline for the management of reproductive health in rheumatic and musculoskeletal diseases","volume":"72","author":"Sammaritano","year":"2020","journal-title":"Arthritis Care Res"},{"key":"2026032910412619000_53.3.292.15","doi-asserted-by":"crossref","first-page":"910","DOI":"10.1016\/j.ard.2025.02.023","article-title":"EULAR recommendations for use of antirheumatic drugs in reproduction, pregnancy, and lactation: 2024 update","volume":"84","author":"R\u00fcegg","year":"2025","journal-title":"Ann Rheum Dis"},{"key":"2026032910412619000_53.3.292.16","doi-asserted-by":"crossref","first-page":"1561","DOI":"10.1016\/j.ard.2025.02.021","article-title":"Antirheumatic drugs in reproduction, pregnancy, and lactation: a systematic literature review informing the 2024 update of the EULAR recommendations","volume":"84","author":"Pluma","year":"2025","journal-title":"Ann Rheum Dis"}],"container-title":["The Journal of Rheumatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.3899\/jrheum.2025-0757","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,3,29]],"date-time":"2026-03-29T17:41:59Z","timestamp":1774806119000},"score":1,"resource":{"primary":{"URL":"http:\/\/www.jrheum.org\/lookup\/doi\/10.3899\/jrheum.2025-0757"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12,1]]},"references-count":16,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2026,3,1]]},"published-print":{"date-parts":[[2026,3]]}},"alternative-id":["10.3899\/jrheum.2025-0757"],"URL":"https:\/\/doi.org\/10.3899\/jrheum.2025-0757","relation":{},"ISSN":["0315-162X","1499-2752"],"issn-type":[{"value":"0315-162X","type":"print"},{"value":"1499-2752","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,12,1]]}}}